Assessment of topical microbicides to prevent HIV-1 transmission: Concepts, testing, lessons learned

Antiviral Research

Volumn 99, Issue 3, 2013, Pages 391-400

  Friend, David R ^a   Kiser, Patrick F ^b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b University of Utah   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Adherence; Intravaginal rings; Microbicide; Multipurpose prevention technologies; Pre exposure prophylaxis; Vaginal gels

Indexed keywords

C 31G; CARBOPOL 974P; CARRAGEENAN; CARRAGUARDT; CELLULOSE SULFATE; DAPIVIRINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETHINYLESTRADIOL PLUS ETONOGESTREL; MARAVIROC; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; MIV 150; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONOXINOL 9; PLACEBO; POLYANION; PRO 2000; SURFACTANT; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZINC ACETATE; ZINC DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TOPICAL ANTIINFECTIVE AGENT; HPTN 035; MDP 301; SILICONE;

CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; DISEASE PREDISPOSITION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SOUTH AFRICA; TOPICAL TREATMENT; VAGINA RING; VIRUS TRANSMISSION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; TRANSMISSION; VIROLOGY; ADHERENCE; DISEASE TRANSMISSION; DRUG EFFECT; INTRAVAGINAL RINGS; MULTIPURPOSE PREVENTION TECHNOLOGIES; PRE-EXPOSURE PROPHYLAXIS; VAGINAL GELS; ANTIVIRAL ACTIVITY; SEROCONVERSION;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE;

ADHERENCE; INTRAVAGINAL RINGS; MICROBICIDE; MULTIPURPOSE PREVENTION TECHNOLOGIES; PRE-EXPOSURE PROPHYLAXIS; VAGINAL GELS;

EID: 84884555284     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.06.021     Document Type: Review

References (124)

1. Abbas, U., Glaubius, R., Mubayi, A., Mellors, J., 2011. Predicting the impact of ART and PrEP with overlapping regimens on HIV transmission and drug resistance in South Africa. 18th Conf. on Retrovir. Opportunistic Infect. Abstract #98LB, Boston, MA.
2. Abdool Karim Q., Abdool Karim S.S, Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B.M., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D., Groupo b.o.t.C.T. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of hiv infection in women. Science 2010, 329:1168-1174.
3. Abdool Karim S.S., Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract. amp Res. Clin. Obstet. am Gynaecol. 2012, 26:427-439.
4. Abdool Karim S.S., Richardson B.A., Ramjee G., Hoffman I.F., Chirenje Z.M., Taha T., Kapina M., Maslankowski L., Coletti A., Profy A., Moench T.R., Piwowar-Manning E., Masse B., Hillier S.L., Soto-Torres L., Team H.I.V.P.T.N.S. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011, 25:957-966.
5. Achilles S.L., Shete P.B., Whaley K.J., Moench T.R., Cone R.A. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis. 2002, 29:655-664.
6. Anton P.A., Cranston R.D., Kashuba A., Hendrix C.W., Bumpus N.N., Richardson-Harman N., Elliott J., Janocko L., Khanukhova E., Dennis R., Cumberland W.G., Ju C., Carballo-Dieguez A., Mauck C., McGowan I. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses 2012, 28:1412-1421.
7. Arens M., Travis S. Zinc salts inactivate clinical isolates of herpes simplex virus in vitro. J. Clin. Microbiol. 2000, 38:1758-1762.
8. Asculai S.S., Weis M.T., Rancourt M.W., Kupferberg A.B. Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob. Agents Chemother. 1978, 13:686-690.
9. Baba M., Nakajima M., Schols D., Pauwels R., Balzarini J., De Clercq E. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res. 1988, 9:335-343.
10. Balzarini J., Aquaro S., Perno C.F., Witvrouw M., Holý A., De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 1996, 219:337-341.
11. Balzarini J., Holy A., Jindrich J., Naesens L., Snoeck R., Schols D., De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 1993, 37:332-338.
12. Bax R., Douville K., McCormick D., Rosenberg M., Higgins J., Bowden M. Microbicides-evaluating multiple formulations of C31G. Contraception 2002, 66:365-368.
13. Bourne N., Stegall R., Montano R., Meador M., Stanberry L.R., Milligan G.N. Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob. Agents Chemother. 2005, 49:1181-1183.
14. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006, 2:e69.
15. Burke A.E., Barnhart K., Jensen J.T., Creinin M.D., Walsh T.L., Wan L.S., Westhoff C., Thomas M., Archer D., Wu H., Liu J., Schlaff W., Carr B.R., Blithe D. Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial. Obstet. Gynecol. 2010, 116:1265-1273.
16. Carballo-Dieguez A., Balan I.C., Morrow K., Rosen R., Mantell J.E., Gai F., Hoffman S., Maslankowski L., El-Sadr W., Mayer K. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a phase I clinical trial (HPTN 050). AIDS Care 2007, 19:1026-1031.
17. Cassell M.M., Halperin D.T., Shelton J.D., Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention?. BMJ 2006, 332:605-607.
18. Catalone B.J., Kish-Catalone T.M., Budgeon L.R., Neely E.B., Ferguson M., Krebs F.C., Howett M.K., Labib M., Rando R., Wigdahl B. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob. Agents Chemother. 2004, 48:1837-1847.
19. Celum C., Baeten J.M. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr. Opin. Infect. Dis. 2012, 25:51-57.
20. Chen J., Flexner C., Liberman R.G., Skipper P.L., Louissaint N.A., Tannenbaum S.R., Hendrix C.W., Fuchs E.J. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J. Acquir. Immune Defic. Syndr. 2012, 61:593-599.
21. Cheshenko N., Keller M.J., MasCasullo V., Jarvis G.A., Cheng H., John M., Li J.H., Hogarty K., Anderson R.A., Waller D.P., Zaneveld L.J., Profy A.T., Klotman M.E., Herold B.C. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. 2004, 48:2025-2036.
22. Clark J.T., Johnson T.J., Clark M.R., Nebeker J.S., Fabian J., Tuitupou A.L., Ponnapalli S., Smith E.M., Friend D.R., Kiser P.F. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J. Control Release 2012, 163:240-248.
23. Clark M.R., Friend D.R. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. AIDS Res. Hum. Retroviruses 2012, 28:1458-1466.
24. Cohen M.S., Muessig K.E., Smith M.K., Powers K.A., Kashuba A.D.M. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (Hagerstown, MD, United States) 2012, 26:1585-1598.
25. Crook A.M., Nunn A.J. Statistical and methodological issues in microbicide trial design. Best Pract. Res. Clin. Obstet. Gynaecol. 2012, 26:463-471.
26. Dezzutti C.S., James V.N., Ramos A., Sullivan S.T., Siddig A., Bush T.J., Grohskopf L.A., Paxton L., Subbarao S., Hart C.E. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 2004, 48:3834-3844.
27. Dobard C., Sharma S., Martin A., Pau C.-P., Holder A., Kuklenyik Z., Lipscomb J., Hanson D.L., Smith J., Novembre F.J., García-Lerma J.G., Heneine W. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J. Virol. 2012, 86:718-725.
28. Feldblum P.J., Adeiga A., Bakare R., Wevill S., Lendvay A., Obadaki F., Olayemi M.O., Wang L., Nanda K., Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008, 3:e1474.
29. Fernandez-Romero J.A., Abraham C.J., Rodriguez A., Kizima L., Jean-Pierre N., Menon R., Begay O., Seidor S., Ford B.E., Gil P.I., Peters J., Katz D., Robbiani M., Zydowsky T.M. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob. Agents Chemother. 2012, 56:358-368.
30. Fernandez-Romero J.A.B.S., Thorn M.M.S., Turville S.G.P., Titchen K.B.S., Sudol K.B.S., Li J.P., Miller T.B.S., Robbiani M.P., Maguire R.A.B.S., Buckheit R.W.J.P., Hartman T.L.M.S., Phillips D.M.P. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis. 2007, 34:9-14.
31. Fetherston S.M., Boyd P., McCoy C.F., McBride M.C., Edwards K.-L., Ampofo S., Malcolm R.K. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur. J. Pharm. Sci. 2013, 48:406-415.
32. Fichorova R.N., Bajpai M., Chandra N., Hsiu J.G., Spangler M., Ratnam V., Doncel G.F. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 2004, 71:761-769.
33. Fichorova R.N., Tucker L.D., Anderson D.J. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 2001, 184:418-428.
34. Fletcher P., Harman S., Azijn H., Armanasco N., Manlow P., Perumal D., de Bethune M.P., Nuttall J., Romano J., Shattock R. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 2009, 53:487-495.
35. Friend D.R. Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections. Drug Del. Transl. Res. 2011, 1:185-193.
36. Friend D.R. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin. Drug Deliv. 2012, 9:417-427.
37. Friend D.R., Doncel G.F. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res. 2010, 88(Suppl. 1):S47-54.
38. Grant R.M., Hamer D., Hope T., Johnston R., Lange J., Lederman M.M., Lieberman J., Miller C.J., Moore J.P., Mosier D.E., Richman D.D., Schooley R.T., Springer M.S., Veazey R.S., Wainberg M.A. Whither or wither microbicides?. Science 2008, 321:532-534.
39. Halpern V., Ogunsola F., Obunge O., Wang C.H., Onyejepu N., Oduyebo O., Taylor D., McNeil L., Mehta N., Umo-Otong J., Otusanya S., Crucitti T., Abdellati S. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One 2008, 3:e3784.
40. Haraguchi Y., Sakurai H., Hussain S., Anner B.M., Hoshino H. Inhibition of HIV-1 infection by zinc group metal compounds. Antiviral Res. 1999, 43:123-133.
41. Harrison P.F., Hemmerling A., Romano J., Whaley K.J., Young Holt B. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res. Treat. 2013, 2013:790154.
42. Hemmerling A., Harrison W.G., Brown J.M., Moscicki B., Oziemkowska M., Bukusi E.A., Cohen C.R. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012, 39:710-712.
43. Hendrix C.W., Chen B.A., Guddera V., Hoesley C., Justman J., Nakabiito C., Salata R., Soto-Torres L., Patterson K., Minnis A.M., Gandham S., Gomez K., Richardson B.A., Bumpus N.N. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013, 8:e55013.
44. Herold B.C., Mesquita P.M., Madan R.P., Keller M.J. Female genital tract secretions and semen impact the development of microbicides for the prevention of hiv and other sexually transmitted infections. Am. J. Reprod. Immunol. 2011, 65:325-333.
45. Hicks D.R., Martin L.S., Getchell J.P., Heath J.L., Francis D.P., McDougal J.S., Curran J.W., Voeller B. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 1985, 2:1422-1423.
46. Hogarty, K., Kasowitz, A., Herold, B.C., Keller, M.J., 2007. Assessment of Adherence to Product Dosing in a Pilot Microbicide Study. Sexually Transmitted Diseases December 34, 1000-1003.
47. Ito M., Baba M., Sato A., Pauwels R., De Clercq E., Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res. 1987, 7:361-367.
48. Johnson T.J., Clark M.R., Albright T.H., Nebeker J.S., Tuitupou A.L., Clark J.T., Fabian J., McCabe R.T., Chandra N., Doncel G.F., Friend D.R., Kiser P.F. A 90-day tenofovir reservoir intravaginal ring for mucosal hiv prophylaxis. Antimicrob. Agents Chemother. 2012, 56:6272-6283.
49. Karim S.S., Kashuba A.D., Werner L., Karim Q.A. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011, 378:279-281.
50. Keller M.J., Mesquita P.M.M., Torres N.M., Cho S., Shust G., Madan R.P., Cohen H.W., Petrie J., Ford T., Soto-Torres L., Profy A.T., Herold B.C. Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical Trials. PLoS One 2010, 5:e8781.
51. Kenney J., Aravantinou M., Singer R., Hsu M., Rodriguez A., Kizima L., Abraham C.J., Menon R., Seidor S., Chudolij A., Gettie A., Blanchard J., Lifson J.D., Piatak M., Fernández-Romero J.A., Zydowsky T.M., Robbiani M. An Antiretroviral/Zinc combination gel provides 24h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011, 6:e15835.
52. Kiser P.F., Johnson T.J., Clark J.T. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012, 14:62-77.
53. Kiser P.F., Mesquita P.M., Herold B.C. A perspective on progress and gaps in HIV prevention science. AIDS Res. Hum. Retroviruses 2012, 28:1373-1378.
54. Krebs F.C., Miller S.R., Catalone B.J., Welsh P.A., Malamud D., Howett M.K., Wigdahl B. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob. Agents Chemother. 2000, 44:1954-1960.
55. Krebs F.C., Miller S.R., Malamud D., Howett M.K., Wigdahl B. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 1999, 43:157-173.
56. Kruk M.E., Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin. Ther. 2006, 28:1989-1995.
57. Lallemant M., Jourdain G. Preventing mother-to-child transmission of HIV-protecting this generation and the next. New Engl. J. Med. 2010, 363:1570-1572.
58. Maguire R., Zacharopoulos V., Phillips D. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex Transm Dis. 1998, 25:494-500.
59. Malcolm K., Fetherston S.M., McCoy C.F., Boyd P., Major I. Vaginal rings for delivery of HIV microbicides. Int. J. Women's Health 2012, 4:595-605.
60. Malcolm R.K., Veazey R.S., Geer L., Lowry D., Fetherston S.M., Murphy D.J., Boyd P., Major I., Shattock R.J., Klasse P.J., Doyle L.A., Rasmussen K.K., Goldman L., Ketas T.J., Moore J.P. Sustained Release of the CCR5 Inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother. 2012, 56:2251-2258.
61. Malkovsky M., Newell A., Dalgleish A.G. Inactivation of HIV by nonoxynol-9. Lancet 1988, 1:645.
62. Marais D., Gawarecki D., Allan B., Ahmed K., Altini L., Cassim N., Gopolang F., Hoffman M., Ramjee G., Williamson A.L. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir. Ther. 2011, 16:1219-1226.
63. Marrazzo, J.M., Ramjee, G., Nair, G., Palanee, T., Mkhize, B., Nakabbiito, C., Taljaard, M., Piper, J., Gomez Feliciano, K., Chirenje, M., 2013. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN-003), 2013 Conference on Retroviruses and Opportunistic Infections Atlanta, GA.
64. Martin L.S., Loskoski S.L., McDougal J.S. Inactivation of human T-lymphotropic virus type III/lymphadenopathy-associated virus by formaldehyde-based reagents. Appl. Environ. Microbiol. 1987, 53:708-709.
65. Marx P.A., Spira A.I., Gettie A., Dailey P.J., Veazey R.S., Lackner A.A., Mahoney C.J., Miller C.J., Claypool L.E., Ho D.D., Alexander N.J. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 1996, 2:1084-1089.
66. Mauck C.K., Creinin M.D., Barnhart K.T., Ballagh S.A., Archer D.F., Callahan M.M., Schmitz S.W., Bax R. A phase I comparative postcoital testing study of three concentrations of C31G. Contraception 2004, 70:227-231.
67. Mauck C.K., Frezieres R.G., Walsh T.L., Schmitz S.W., Callahan M.M., Bax R. Male tolerance study of 1% C31G. Contraception 2004, 70:221-225.
68. Mauck C.K., Weiner D.H., Creinin M.D., Barnhart K.T., Callahan M.M., Bax R. A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength gynol II. Contraception 2004, 70:233-240.
69. Mayer K.H., Maslankowski L.A., Gai F., El-Sadr W.M., Justman J., Kwiecien A., Mâsse B., Eshleman S.H., Hendrix C., Morrow K., Rooney J.F., Soto-Torres L., Team t.H.P. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006, 20:543-551.
70. Mayer K.H., Peipert J., Fleming T., Fullem A., Moench T., Cu-Uvin S., Bentley M., Chesney M., Rosenberg Z. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin. Infect. Dis. 2001, 32:476-482.
71. McCormack S., Ramjee G., Kamali A., Rees H., Crook A.M., Gafos M., Jentsch U., Pool R., Chisembele M., Kapiga S., Mutemwa R., Vallely A., Palanee T., Sookrajh Y., Lacey C.J., Darbyshire J., Grosskurth H., Profy A., Nunn A., Hayes R., Weber J. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337.
72. McGowan I., Hoesley C., Cranston R.D., Andrew P., Janocko L., Dai J.Y., Carballo-Dieguez A., Ayudhya R.K.N., Piper J., Hladik F., Mayer K. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS ONE 2013, 8:e60147.
73. Mesquita P.M., Cheshenko N., Wilson S.S., Mhatre M., Guzman E., Fakioglu E., Keller M.J., Herold B.C. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J. Infect. Dis. 2009, 200:599-608.
74. Mesquita P.M., Rastogi R., Segarra T.J., Teller R.S., Torres N.M., Huber A.M., Kiser P.F., Herold B.C. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J. Antimicrob. Chemother. 2012, 67:1730-1738.
75. Miller C.J., Alexander N.J., Gettie A., Hendrickx A.G., Marx P.A. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil. Steril. 1992, 57:1126-1128.
76. Mitsuya H., Looney D.J., Kuno S., Ueno R., Wong-Staal F., Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 1988, 240:646-649.
77. Moench T.R., O'Hanlon D., Cone E. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012, 39:335-340.
78. Montgomery E., van der Straten A., Cheng H., Wegner L., Masenga G., von Mollendorf C., Bekker L., Ganesh S., Young K., Romano J., Nel A., Woodsong C. Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012, 16:1787-1798.
79. Novák A., de la Loge C., Abetz L., van der Meulen E.A. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception 2003, 67:187-194.
80. Olmsted S.S., Dubin N.H., Cone R.A., Moench T.R. The rate at which human sperm are immobilized and killed by mild acidity. Fertil. Steril. 2000, 73:687-693.
81. Ongradi J., Ceccherini-Nelli L., Pistello M., Specter S., Bendinelli M. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res. Hum. Retroviruses 1990, 6:1433-1436.
82. Parikh U.M., Dobard C., Sharma S., Cong M.E., Jia H., Martin A., Pau C.P., Hanson D.L., Guenthner P., Smith J., Kersh E., Garcia-Lerma J.G., Novembre F.J., Otten R., Folks T., Heneine W. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 2009, 83:10358-10365.
83. Patton D.L., Cosgrove Sweeney Y.T., Paul K.J. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Sex Transm Dis. 2008, 35:889-897.
84. Pearce-Pratt R., Phillips D.M. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 1996, 54:173-182.
85. Peterson L., Nanda K., Opoku B.K., Ampofo W.K., Owusu-Amoako M., Boakye A.Y., Rountree W., Troxler A., Dominik R., Roddy R., Dorflinger L. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007, 2:e1312.
86. Pirrone V., Wigdahl B., Krebs F.C. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011, 90:168-182.
87. Robbins B.L., Srinivas R.V., Kim C., Bischofberger N., Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 1998, 42:612-617.
88. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., Lowy D.R., Schiller J.T. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 2007, 13:857-861.
89. Romano J.W., Robbiani M., Doncel G.F., Moench T. Non-specific microbicide product development: then and now. Curr. HIV Res. 2012, 10:9-18.
90. Rosen, R.K., Morrow, K.M., Carballo-Dieguez, A., Mantell, J.E., Hoffman, S., Gai, F., Maslankowski, L., El-Sadr, W. M., Mayer, K.H., 2008. Acceptability of Tenofovir Gel as a Vaginal Microbicide Among Women in a Phase I Trial: A Mixed-Methods Study. Journal of Women's Health (15409996) 17, 383-392.
91. Roumen F., Dieben T., Assendorp R., Bouckaert P. The clinical acceptability of a non-medicated vaginal ring. Contraception 1990, 42:201-207.
92. Rusconi S., Moonis M., Merrill D.P., Pallai P.V., Neidhardt E.A., Singh S.K., Willis K.J., Osburne M.S., Profy A.T., Jenson J.C., Hirsch M.S. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 1996, 40:234-236.
93. Singer R., Derby N., Rodriguez A., Kizima L., Kenney J., Aravantinou M., Chudolij A., Gettie A., Blanchard J., Lifson J.D., Piatak M., Fernandez-Romero J.A., Zydowsky T.M., Robbiani M. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011, 85:5504-5512.
94. Singer, R., Mawson, P., Derby, N., Rodriguez, A., Kizima, L., Menon, R., Goldman, D., Kenney, J., Aravantinou, M., Seidor, S., Gettie, A., Blanchard, J., Piatak, M., Lifson, J.D., Fernández-Romero, J.A., Robbiani, M., Zydowsky, T.M., 2012. An Intravaginal Ring That Releases the NNRTI MIV-150 Reduces SHIV Transmission in Macaques. Science Translational Medicine 4, 150ra123, http://dx.doi.org/10.1126/scitranslmed.3003936.
95. Skoler-Karpoff S., Ramjee G., Ahmed K., Altini L., Plagianos M.G., Friedland B., Govender S., De Kock A., Cassim N., Palanee T., Dozier G., Maguire R., Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1977-1987.
96. Smith, D.J., Wakasiaka, S., Hoang, T.D.M., Bwayo, J.J., del Rio, C., Priddy, F.H., 2008. An Evaluation of Intravaginal Rings as a Potential HIV Prevention Device in Urban Kenya: Behaviors and Attitudes That Might Influence Uptake within a High-Risk Population. Journal of Women's Health 17, 1025-1034.
97. Smith J., Rastogi R., Teller R., Srinivasan P., Mitchell J., McNicholl J., Hendry M., Mesquita P.M., Kiser P., Herold B. A tenofovir disoproxil fumarate intravaginal ring completely protects against repeated SHIV challenge in nonhuman primates, 2013 conference on retroviruses and opportunistic infections 2013, Atlanta, GA.
98. Sokal D.C., Karim Q.A., Sibeko S., Yende-Zuma N., Mansoor L.E., Baxter C., Grobler A., Frolich J., Kharsany A.B., Omar Z., Miya N., Mlisana K., Maarshalk S., Karim S.S. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 trial. Antivir. Ther. 2013, 18:301-310.
99. Spencer S.E., Valentin-Bon I.E., Whaley K., Jerse A.E. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J. Infect. Dis. 2004, 189:410-419.
100. Srinivas R.V., Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 1998, 42:1484-1487.
101. Stein Z.A. HIV prevention: the need for methods women can use. Am. J. Public Health 1990, 80:460-462.
102. Stein Z.A. Vaginal microbicides and prevention of HIV infection. Lancet 1994, 343:362-363.
103. Terrazas-Aranda K., Van Herrewege Y., Lewi P.J., Van Roey J., Vanham G. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir. Chem. Chemother. 2007, 18:141-151.
104. Thompson K.A., Malamud D., Storey B.T. Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9. Contraception 1996, 53:313-318.
105. Thurman A.R., Clark M.R., Doncel G.F. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect. Dis. Obstet. Gynecol. 2011, 2011:1-10.
106. Turville S.G., Aravantinou M., Miller T., Kenney J., Teitelbaum A., Hu L., Chudolij A., Zydowsky T.M., Piatak M., Bess J.W., Lifson J.D., Blanchard J., Gettie A., Robbiani M. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008, 3:e3162.
107. Uberla K., Stahl-Hennig C., Bottiger D., Matz-Rensing K., Kaup F.J., Li J., Haseltine W.A., Fleckenstein B., Hunsmann G., Oberg B., et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 1995, 92:8210-8214.
108. Van Damme L., Chandeying V., Ramjee G., Rees H., Sirivongrangson P., Laga M., Perriens J. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II study group. AIDS 2000, 14:85-88.
109. Van Damme L., Corneli A., Ahmed K., Agot K., Lombaard J., Kapiga S., Malahleha M., Owino F., Manongi R., Onyango J., Temu L., Monedi M.C., Mak'Oketch P., Makanda M., Reblin I., Makatu S.E., Saylor L., Kiernan H., Kirkendale S., Wong C., Grant R., Kashuba A., Nanda K., Mandala J., Fransen K., Deese J., Crucitti T., Mastro T.D., Taylor D. Preexposure Prophylaxis for HIV Infection among African Women. New Engl. J. Med. 2012, 367:411-422.
110. Van Damme L., Govinden R., Mirembe F.M., Guedou F., Solomon S., Becker M.L., Pradeep B.S., Krishnan A.K., Alary M., Pande B., Ramjee G., Deese J., Crucitti T., Taylor D. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal hiv transmission. New Engl. J. Med. 2008, 359:463-472. the CS Study Group.
111. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., Sirivongrangson P., Tshibaka L.M., Ettiègne-Traoré V., Uaheowitchai C., Karim S.S.A., Mâsse B., Perriëns J., Laga M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977.
112. van De Wijgert J., Fullem A., Kelly C., Mehendale S., Rugpao S., Kumwenda N., Chirenje Z., Joshi S., Taha T., Padian N., Bollinger R., Nelson K. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J. Acquir. Immune Defic. Syndr. 2001, 26:21-27.
113. van der Straten A., Montgomery E., Cheng H., Wegner L., Masenga G., von Mollendorf C., Bekker L., Ganesh S., Young K., Romano J., Nel A., Woodsong C. High acceptability of a vaginal ring intended as a microbicide delivery method for hiv prevention in African women. AIDS Behav. 2012, 16:1775-1786.
114. Van Herrewege Y., Michiels J., Van Roey J., Fransen K., Kestens L., Balzarini J., Lewi P., Vanham G., Janssen P. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 2004, 48:337-339.
115. Van Rompay K.K., Cherrington J.M., Marthas M.L., Berardi C.J., Mulato A.S., Spinner A., Tarara R.P., Canfield D.R., Telm S., Bischofberger N., Pedersen N.C. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 1996, 40:2586-2591.
116. Vandebosch A., Goetghebeur E., Ramjee G., Alary M., Ettiegne-Traore V., Chandeying V., Damme L., Group C.O.L.S. Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex Transm Infect. 2004, 80:241-243.
117. Veronese F., Anton P., Fletcher C.V., DeGruttola V., McGowan I., Becker S., Zwerski S., Burns D. Implications of HIV PrEP trials results. AIDS Res. Hum. Retroviruses 2011, 27:81-90.
118. Vissers D.C., Voeten H.A., Nagelkerke N.J., Habbema J.D., de Vlas S.J. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 2008, 3:e2077.
119. Wallace, A.B.S., Thorn, M.M.S., Maguire, R.A.B.S., Sudol, K.M.B.A., Phillips, D.M.P., 2004. Assay for Establishing Whether Microbicide Applicators Have Been Exposed to the Vagina. Sexually Transmitted Diseases August 31, 465-468.
120. Wyrick P.B., Knight S.T., Gerbig D.G., Raulston J.E., Davis C.H., Paul T.R., Malamud D. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrob. Agents Chemother. 1997, 41:1335-1344.
121. Zacharopoulos V.R., Phillips D.M. Cell-mediated HTLV-I infection of a cervix-derived epithelial cell line. Microb. pathog. 1997, 23:225-233.
122. Zalenskaya I.A., Cerocchi O.G., Joseph T., Donaghay M.A., Schriver S.D., Doncel G.F. Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection. Am. J. Reprod. Immunol. 2011, 65:569-577.
123. Zaretzky F.R., Pearce-Pratt R., Phillips D.M. Sulfated polyanions block Chlamydia trachomatis infection of cervix-derived human epithelia. Infection and immunity 1995, 63:3520-3526.
124. Zeitlin L., Hoen T.E., Achilles S.L., Hegarty T.A., Jerse A.E., Kreider J.W., Olmsted S.S., Whaley K.J., Cone R.A., Moench T.R. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis. 2001, 28:417-423.